Kymera Therapeutics, Inc. (KYMR) reported a loss of 82 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 83 cents. In the year-ago quarter, Kymera reported a loss of 90 cents per share.Collaboration revenues totaled $3.7 million, which missed the Zacks Consensus Estimate of $9 million. The reported figure increased 20.8% from the year-ago level.Collaboration revenues in the third quarter were mostly earned due to the company’s association with bigwig Sanof ...

Core Viewpoint - Kymera Therapeutics reported a quarterly loss of $0.82 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.83, and an improvement from a loss of $0.90 per share a year ago [1][2] Financial Performance - The company posted revenues of $3.74 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 58.27%, compared to $4.73 million in revenues a year ago [2] - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Kymera Therapeutics shares have increased approximately 87.2% since the beginning of the year, outperforming the S&P 500's gain of 21.9% [3] Future Outlook - The current consensus EPS estimate for the coming quarter is -$0.78 on revenues of $13.41 million, and for the current fiscal year, it is -$2.85 on revenues of $58.33 million [7] - The estimate revisions trend for Kymera Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-39460 KYMERA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter ...

Core Insights - Kymera Therapeutics has received FDA clearance for its investigational New Drug application for KT-621, a first-in-class oral STAT6 degrader aimed at treating multiple allergic and atopic diseases [1][3] - The company plans to initiate a phase I study for KT-621 in healthy volunteers later this month, with data expected in the first half of 2025 [2] Company Pipeline Progress - Kymera recently raised $225 million through a public offering to advance its pipeline of degrader programs [5] - The company is also progressing with KT-474, a first-in-class IRAK4 degrader, with plans for pivotal studies following positive preliminary safety and efficacy data [6][7] - Ongoing phase I studies for KT-253 and KT-333 are showing promising antitumor responses, with enrollment expected to complete in the second half of 2024 [9][10] Competitive Landscape - Sanofi and Regeneron's Dupixent, an injectable monoclonal antibody, is an established therapy for allergic and atopic diseases, validating the STAT6 targeting approach [4]

KT-621 has demonstrated dupilumab-like activity and was well tolerated in a wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the clearance of its Investigational New Drug (I ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human sensory neurons resulting in inhibition of IL-13- induced itch- and pain-related gene transcripts with the potential to alleviate these symptoms in atopic dermatitis patients KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 WATERTOWN, Mass., Sept. 25, 2024 (GL ...

Core Insights - Kymera Therapeutics reported a narrower loss of 58 cents per share in Q2 2024, better than the expected loss of 69 cents, and improved from a loss of 67 cents per share in the same quarter last year [2][15] - The company experienced a significant increase in collaboration revenues, totaling $25.6 million, which exceeded the consensus estimate of $12 million and represented a 55.3% increase year-over-year [2][3] Financial Performance - Research and development expenses rose to $59.2 million, a 29.3% increase year-over-year, driven by investments in the targeted protein degradation platform and increased occupancy costs [4] - General and administrative expenses increased to $17.4 million, up 22.9% year-over-year, primarily due to higher legal and professional service fees [5] - As of June 30, 2024, the company had $702.4 million in cash and equivalents, expected to last into the first half of 2027, providing a financial cushion for ongoing and upcoming clinical trials [6] Pipeline Developments - Sanofi plans to expand mid-stage studies on KT-474 towards pivotal studies, a first-in-class IRAK4 degrader for immune-inflammatory diseases [7][8] - Kymera is set to initiate a phase I study on KT-621 in the second half of 2024, with data expected in the first half of 2025 [9] - Ongoing phase I studies for KT-253 and KT-333 have shown promising results, with KT-253 demonstrating antitumor activity in various tumor types and KT-333 showing responses in hematological malignancies [11][13][14] Market Position and Outlook - Estimates for Kymera Therapeutics have trended downward, with a consensus estimate shift of -11.79% [15] - The company holds a Zacks Rank of 3 (Hold), indicating expectations for an in-line return in the coming months [17] - In comparison, Denali Therapeutics, a peer in the biomedical industry, has seen a 13.3% gain over the past month, highlighting competitive dynamics within the sector [18]

WATERTOWN, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats and presentations at the following upcoming investor events: Wells Fargo 2024 Healthcare Conference in Boston, MA on September 4 at 3:00 p.m. ET; Morgan Stanley 22nd Annual Global Healthcare Conference in New York, ...

Company Overview - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small molecule medicines using targeted protein degradation (TPD) [5] - The company aims to address critical health problems and improve patients' lives by deploying TPD to target disease pathways that are inaccessible with conventional therapeutics [5] - Kymera has advanced its first degrader into clinical trials for immunological diseases and is also developing oncology programs targeting undrugged or poorly drugged proteins [5] Recent Financial Activity - Kymera Therapeutics announced the closing of an upsized underwritten public offering totaling $225 million, which included common stock and pre-funded warrants [1] - The company sold 2,830,533 shares of common stock at a public offering price of $40.75 per share, along with pre-funded warrants to purchase 3,519,159 shares at a price of $40.7499 each [1] - The gross proceeds from the offering were approximately $258.75 million before deducting underwriting discounts and commissions [1] Underwriters and Regulatory Compliance - Morgan Stanley, J.P. Morgan, TD Cowen, and Stifel acted as joint book-running managers for the offering [2] - The securities were offered under an automatically effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) [3]

Kymera Therapeutics, Inc. (KYMR) announced the pricing of its underwritten public offering of $225 million of shares of its common stock. The company is selling approximately 2 million shares of common stock at a public offering price of $40.75 per share. In addition, it is selling pre-funded warrants to purchase 3.5 million shares in the offering in lieu of common stock to certain investors. The pre-funded warrants are being sold at a public offering price of $40.7499 per pre-funded warrant. This offering ...